[optimal] Re: (no subject)

  • From: "George Henry, CRA, PBT" <ghenry@xxxxxxxxxxxxxx>
  • To: <optimal@xxxxxxxxxxxxx>
  • Date: Fri, 24 Apr 2015 12:03:02 -0500

Likewise.



George E. Henry, CRA, PBT(ASCP)
Wheaton Eye Clinic, Ltd.
2015 N. Main Street
Wheaton IL 60187
630.588.3615


-----Original Message-----
From: optimal-bounce@xxxxxxxxxxxxx [mailto:optimal-bounce@xxxxxxxxxxxxx] On
Behalf Of Tom Steele
Sent: Friday, April 24, 2015 11:57
To: optimal@xxxxxxxxxxxxx
Subject: [optimal] Re: (no subject)

Only for clinical trials and never for day to day testing.

Thank You,

Tom Steele, CRA

Midwest Eye Institute
200 West 103rd Street
Indianapolis, Indiana 46290
317.817.1018
tsteele@xxxxxxxxxxxxxx


CONFIDENTIALITY NOTICE:

This message is intended only for the use of the individual or entity to
which it is addressed and may contain information that is confidential
and/or privileged. If the reader of this message is not the intended
recipient, you are hereby notified that any dissemination, distribution or
copying of this communication is strictly prohibited. If you have
received this communication in error, please notify us immediately by
telephone and return the original message to us at the above email address

-----Original Message-----
From: optimal-bounce@xxxxxxxxxxxxx [mailto:optimal-bounce@xxxxxxxxxxxxx]
On Behalf Of Cunningham, Denise (NIH/NEI) [E]
Sent: Friday, April 24, 2015 12:51 PM
To: <optimal@xxxxxxxxxxxxx>
Subject: [optimal] Re: (no subject)

Never.

On Apr 24, 2015, at 12:34 PM, "Paula Morris"
<paula.morris@xxxxxxxxxxxx<mailto:paula.morris@xxxxxxxxxxxx>> wrote:

Hello colleagues,

I have received an inquiry from the UK about how often Spectralis users in
the US enter the c-curve information when imaging clinical patients, not
just in clinical trials.

Thanks so much for sharing,

P


Other related posts: